{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T14:48:23Z","timestamp":1780930103329,"version":"3.54.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31570053"],"award-info":[{"award-number":["31570053"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Science Foundation of the Jiangsu Higher Education Institutions of China","award":["18KJA310002"],"award-info":[{"award-number":["18KJA310002"]}]},{"name":"Jiangsu Specially Appointed Professor and Jiangsu Medical Specialist Programs of China"},{"name":"Jiangsu Province \u201cInnovative and Entrepreneurial Team\u201d Program"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.diagmicrobio.2020.115129","type":"journal-article","created":{"date-parts":[[2020,7,8]],"date-time":"2020-07-08T11:48:36Z","timestamp":1594208916000},"page":"115129","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["In vitro activity of new tetracycline analogues omadacycline and eravacycline against clinical isolates of Helicobacter pylori collected in China"],"prefix":"10.1016","volume":"98","author":[{"given":"Yanmei","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijun","family":"Bian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xudong","family":"Hang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caiwang","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoxin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangfu","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongkai","family":"Bi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.diagmicrobio.2020.115129_bb0005","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1093\/jac\/dkz267","article-title":"Omadacycline as a promising new agent for the treatment of infections with Mycobacterium abscessus","volume":"74","author":"Bax","year":"2019","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"10.1016\/j.diagmicrobio.2020.115129_bb0010","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02262-18","article-title":"Antimicrobial activity of omadacycline tested against clinical bacterial isolates from hospitals in mainland China, Hong Kong, and Taiwan: results from the SENTRY antimicrobial surveillance program (2013 to 2016)","volume":"63","author":"Carvalhaes","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.diagmicrobio.2020.115129_bb0015","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa1909666","article-title":"Family history of gastric cancer and Helicobacter pylori treatment","volume":"382","author":"Choi","year":"2020","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.diagmicrobio.2020.115129_bb0020","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1056\/NEJMoa1708423","article-title":"Helicobacter pylori therapy for the prevention of metachronous gastric cancer","volume":"378","author":"Choi","year":"2018","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.diagmicrobio.2020.115129_bb0025","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1099\/jmm.0.001051","article-title":"Real-time PCR detection of a 16S rRNA single mutation of Helicobacter pylori isolates associated with reduced susceptibility and resistance to tetracycline in the gastroesophageal mucosa of individual hosts","volume":"68","author":"Contreras","year":"2019","journal-title":"J Med Microbiol"},{"issue":"3","key":"10.1016\/j.diagmicrobio.2020.115129_bb0030","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1128\/AAC.01066-13","article-title":"Mechanism of action of the novel aminomethylcycline antibiotic omadacycline","volume":"58","author":"Draper","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2020.115129_bb0035","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.diagmicrobio.2018.11.010","article-title":"Minimal inhibitory concentration of omadacycline and doxycycline against bacterial isolates with known tetracycline resistance determinants","volume":"94","author":"Fluit","year":"2019","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"8","key":"10.1016\/j.diagmicrobio.2020.115129_bb0040","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nrgastro.2013.96","article-title":"Helicobacter pylori research: historical insights and future directions","volume":"10","author":"Fock","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"9","key":"10.1016\/j.diagmicrobio.2020.115129_bb0045","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1111\/j.1572-0241.2004.40014.x","article-title":"Eradication therapy in Helicobacter pylori positive peptic ulcer disease: systematic review and economic analysis","volume":"99","author":"Ford","year":"2004","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"10.1016\/j.diagmicrobio.2020.115129_bb0050","doi-asserted-by":"crossref","first-page":"164","DOI":"10.5662\/wjm.v5.i3.164","article-title":"Prevalence of antibiotic resistance in Helicobacter pylori: a recent literature review","volume":"5","author":"Ghotaslou","year":"2015","journal-title":"World J Methodol"},{"key":"10.1016\/j.diagmicrobio.2020.115129_bb0055","first-page":"61(9)","article-title":"Comparison of omadacycline and tigecycline pharmacokinetics in the plasma, epithelial lining fluid, and alveolar cells of healthy adult subjects","author":"Gotfried","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"2 Suppl 1","key":"10.1016\/j.diagmicrobio.2020.115129_bb0060","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/S0016-5085(00)70003-5","article-title":"Therapy of Helicobacter pylori: current status and issues","volume":"118","author":"Graham","year":"2000","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.diagmicrobio.2020.115129_bb0065","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1128\/AAC.06187-11","article-title":"Target- and resistance-based mechanistic studies with TP-434, a novel fluorocycline antibiotic","volume":"56","author":"Grossman","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"10.1016\/j.diagmicrobio.2020.115129_bb0070","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1093\/jac\/dkx147","article-title":"Antimicrobial susceptibility of clinical isolates of Neisseria gonorrhoeae to alternative antimicrobials with therapeutic potential","volume":"72","author":"Lagace-Wiens","year":"2017","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"10.1016\/j.diagmicrobio.2020.115129_bb0075","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02097-19","article-title":"Omadacycline efficacy against Enterococcus faecalis isolated in China: in vitro activity, heteroresistance, and resistance mechanisms","volume":"64","author":"Lin","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2020.115129_bb0080","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3109\/00365529309098341","article-title":"Compliance, adverse events and antibiotic resistance in Helicobacter pylori treatment","volume":"196","author":"Malfertheiner","year":"1993","journal-title":"Scand J Gastroenterol Suppl"},{"issue":"9","key":"10.1016\/j.diagmicrobio.2020.115129_bb0085","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1007\/s40262-019-00767-z","article-title":"Clinical pharmacokinetics and pharmacodynamics of eravacycline","volume":"58","author":"McCarthy","year":"2019","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"10.1016\/j.diagmicrobio.2020.115129_bb0090","article-title":"In vitro activity of eravacycline against Gram-negative bacilli isolated in clinical laboratories worldwide from 2013 to 2017","volume":"64","author":"Morrissey","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"Supplement_1","key":"10.1016\/j.diagmicrobio.2020.115129_bb0095","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1093\/cid\/ciz309","article-title":"Pharmacokinetics and pharmacodynamics of oral and intravenous omadacycline","volume":"69","author":"Rodvold","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2020.115129_bb0100","series-title":"Helicobacter pylori: physiology and genetics","article-title":"Enterohepatic Helicobacter species","author":"Schauer","year":"2001"},{"key":"10.1016\/j.diagmicrobio.2020.115129_bb0105","first-page":"62(5)","article-title":"Evaluation of the in vitro activity of eravacycline against a broad spectrum of recent clinical anaerobic isolates","author":"Snydman","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.diagmicrobio.2020.115129_bb0110","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1001\/jamasurg.2016.4237","article-title":"Assessing the efficacy and safety of eravacycline vs ertapenem in complicated intra-abdominal infections in the Investigating Gram-Negative Infections Treated With Eravacycline (IGNITE 1) trial: a randomized clinical trial","volume":"152","author":"Solomkin","year":"2017","journal-title":"JAMA Surg"},{"issue":"4","key":"10.1016\/j.diagmicrobio.2020.115129_bb0115","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1128\/AAC.01614-13","article-title":"Phase 2, randomized, double-blind study of the efficacy and safety of two dose regimens of eravacycline versus ertapenem for adult community-acquired complicated intra-abdominal infections","volume":"58","author":"Solomkin","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"10.1016\/j.diagmicrobio.2020.115129_bb0120","doi-asserted-by":"crossref","first-page":"5548","DOI":"10.1128\/AAC.01288-13","article-title":"Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens","volume":"57","author":"Sutcliffe","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.diagmicrobio.2020.115129_bb0125","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.ijantimicag.2018.01.001","article-title":"Assessment of in vivo efficacy of eravacycline against Enterobacteriaceae exhibiting various resistance mechanisms: a dose-ranging study and pharmacokinetic\/pharmacodynamic analysis","volume":"51","author":"Thabit","year":"2018","journal-title":"Int J Antimicrob Agents"},{"issue":"8","key":"10.1016\/j.diagmicrobio.2020.115129_bb0130","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1128\/JB.184.8.2131-2140.2002","article-title":"Mutations in the 16S rRNA genes of Helicobacter pylori mediate resistance to tetracycline","volume":"184","author":"Trieber","year":"2002","journal-title":"J Bacteriol"},{"issue":"2","key":"10.1016\/j.diagmicrobio.2020.115129_bb0135","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1128\/AAC.49.2.578-583.2005","article-title":"Tetracycline-resistant clinical Helicobacter pylori isolates with and without mutations in 16S rRNA-encoding genes","volume":"49","author":"Wu","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.diagmicrobio.2020.115129_bb0140","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s40265-016-0545-8","article-title":"Review of eravacycline, a novel fluorocycline antibacterial agent","volume":"76","author":"Zhanel","year":"2016","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.diagmicrobio.2020.115129_bb0145","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s40265-020-01257-4","article-title":"Omadacycline: a novel oral and intravenous aminomethylcycline antibiotic agent","volume":"80","author":"Zhanel","year":"2020","journal-title":"Drugs"}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073288932030506X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073288932030506X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:54:05Z","timestamp":1760003645000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S073288932030506X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S073288932030506X"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2020.115129","relation":{},"ISSN":["0732-8893"],"issn-type":[{"value":"0732-8893","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro activity of new tetracycline analogues omadacycline and eravacycline against clinical isolates of Helicobacter pylori collected in China","name":"articletitle","label":"Article Title"},{"value":"Diagnostic Microbiology and Infectious Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2020.115129","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115129"}}